Our website uses necessary cookies to enable basic functions and optional cookies to help us to enhance your user experience. Learn more about our cookie policy by clicking "Learn More".
Accept All Only Necessary Cookies

Pathfinder8 정보

Pathfinder8은 혈우병 A를 가진 어린이와 사람을 위해 개발되었습니다.

The Pathfinder8 app is developed for people and parents to children with Haemophilia A treated with N8-GP (an extended half-life factor VIII product). The aim of the app is to assist people with haemophilia to self manage their condition and stay on top of their treatment by delivering a variety of features.

The Pathfinder8 app allows you to keep an overview of your:

• treatment plan and history

• bleeding record

• estimated factor VIII level

The Pathfinder8 app enables reminders of:

• scheduled prophylaxis doses

• visit at the clinic/treatment centre

The Pathfinder8 app provides easy access to:

• a digital haemophilia patient card

• useful travel links, guidelines & videos

• communicate your treatment history to your doctor

NOTE FOR APP USERS

The App is not intended to provide medical advice or replace it and no adjustments of treatment should be made solely based on this app. In case you have questions regarding your medical condition, you should always seek advice from your treating physician.

최신 버전 1.0.0의 새로운 기능

Last updated on Mar 31, 2020

The Pathfinder8 app is developed for people and parents to children with Haemophilia A treated with N8-GP (an extended half-life factor VIII product). The aim of the app is to assist people with haemophilia to self manage their condition and stay on top of their treatment by delivering a variety of features.

번역 로드 중...

추가 앱 정보

최신 버전

Pathfinder8 업데이트 요청 1.0.0

업로드한 사람

Techin Sans

필요한 Android 버전

Android 6.0+

더 보기

Pathfinder8 스크린 샷

댓글 로드 중 ...
언어
APKPure를 구독하십시오
최고의 Android 게임 및 앱의 초기 릴리스, 뉴스 및 가이드에 액세스하는 첫 번째 사람이 되십시오.
고맙지 만 사양 할게
가입하기
성공적으로 구독!
당신은 이제 APKPure에 가입되었습니다.
APKPure를 구독하십시오
최고의 Android 게임 및 앱의 초기 릴리스, 뉴스 및 가이드에 액세스하는 첫 번째 사람이 되십시오.
고맙지 만 사양 할게
가입하기
성공!
당신은 이제 우리의 뉴스 레터를 구독하고 있습니다.